Traditional Chinese medicine preparation capable of being combined with gemcitabine for treating pancreatic cancer and improving liver and kidney toxicity
By combining a water extract preparation composed of multiple Chinese medicines with gemcitabine, the liver and kidney toxicity problem of gemcitabine in treating pancreatic cancer is solved, effective pancreatic cancer treatment and toxicity improvement is achieved, and dose adjustment or interruption in the treatment is avoided .
Patent Information
- Application Number
- CN202411194569.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-29
AI Technical Summary
Gemcitabine can produce liver and nephrotoxicity when treating pancreatic cancer, causing patients to need to reduce the dose or interrupt the treatment, limiting its clinical treatment effect.
A Chinese medicine preparation consists of Ganoderma lucidum, Codonopsis pilosula, Poria cocos, serpentium serpentium , white serpentium , raw coix seed, frankincense, myrrh, fried Atractylodes, Citrus aurantium, Bupleurum and Pinellia ternata. It is made of water extract, and can be combined with Combination of gemcitabine improves liver and renal toxicity and avoids reducing the therapeutic dose or interrupting treatment.
This traditional Chinese medicine preparation effectively inhibits the growth of pancreatic cancer, significantly improves the liver and kidney toxicity caused by gemcitabine treatment, ensures that the treatment effect is not reduced, and there is no need to adjust the treatment dose or interrupt the treatment.
Smart Images

Figure CN118924851A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a traditional Chinese medicine preparation, in particular to a traditional Chinese medicine preparation which can be used in combination with gemcitabine to treat pancreatic cancer and improve liver and kidney toxicity. Background Art
[0002] Pancreatic cancer is a highly malignant tumor with a poor prognosis, and its pathogenesis is still unclear. At present, chemotherapy is the main means of clinical treatment of pancreatic cancer, among which gemcitabine (GEM) is widely used as a first-line chemotherapy drug for the treatment of pancreatic cancer. However, gemcitabine can cause liver and kidney toxicity when treating pancreatic cancer, causing patients to reduce the dosage or even interrupt treatment until the toxic reaction of the body disappears before the drug can be used again. For this reason, its clinical treatment effect is greatly limited. Summary of the invention
[0003] The present invention aims to solve the above technical problems existing in the prior art and provides a Chinese medicine preparation which can be used in combination with gemcitabine to treat pancreatic cancer and improve liver and kidney toxicity.
[0004] The technical solution of the present invention is: a Chinese medicine preparation which can be used in combination with gemcitabine to treat pancreatic cancer and improve liver and kidney toxicity, which is a Chinese medicine water extract. The Chinese medicine is composed of the following components and weight fractions: 10-40 ganoderma lucidum, 7.5-30 codonopsis pilosula, 7.5-30 poria cocos, 15-60 barbata scabra, 15-60 oldenlandia diffusa, 15-60 raw coix seeds, 2.5-10 frankincense, 2.5-10 myrrh, 5-20 stir-fried atractylodes macrocephala, 5-20 immature bitter orange, 5-20 bupleurum, 3-12 pinellia ternata, and 3-12 liquorice.
[0005] The present invention uses Codonopsis pilosula, Poria cocos and Ganoderma lucidum together to invigorate qi and strengthen the spleen, replenish but not harsh, replenish the source of the acquired constitution, and treat various deficiencies, so as to achieve the purpose of strengthening the body and strengthening the foundation, and is the main medicine. Scutellaria barbata and Hedyotis diffusa clear away heat and detoxify, eliminate blood stasis and disperse stagnation; Raw Coix seeds are diuretic and dampness-infiltrating, and are the ministerial medicines. Bupleurum soothes the liver and relieves depression, regulates the qi, and Citrus aurantium enters the middle jiao spleen and stomach, promotes qi and disperses stagnation. The two medicines raise the clear and lower the turbid, so that the qi is unobstructed; frankincense, myrrh, and dried toad skin relieve pain; Atractylodes macrocephala strengthens the spleen and dries dampness; Pinellia ternata smoothes qi and harmonizes the middle, and is combined as an adjuvant; Licorice harmonizes all the medicines, and is the guiding medicine. The whole prescription is compatible with drugs to strengthen the body and fight cancer, and both attack and supplement are used, and both the symptoms and the root cause are taken into consideration. More importantly, the liver and kidney toxicity caused by gemcitabine in the treatment of pancreatic cancer can be improved, and there is no need to reduce the treatment dose or interrupt the treatment during treatment, so as to achieve the purpose of effectively treating pancreatic cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0006] Figure 1 This is a schematic diagram of the weight changes of mice in each experimental group after 1-14 days of pancreatic cancer treatment.
[0007] Figure 2 This is a schematic diagram of the changes in tumor volume in each experimental group after 1-14 days of treatment of pancreatic cancer.
[0008] Figure 3 It is a schematic diagram of the tumor mass of each experimental group after treatment of pancreatic cancer.
[0009] Figure 4 This is a schematic diagram of the tumor size in each experimental group after treatment of pancreatic cancer.
[0010] Figure 5 These are the HE staining images of tumor tissue sections after treatment of pancreatic cancer in each experimental group.
[0011] Figure 6 These are the HE staining images of liver and kidney sections after treatment of pancreatic cancer in each experimental group. DETAILED DESCRIPTION
[0012] A Chinese medicine preparation that can be used in combination with gemcitabine to treat pancreatic cancer and improve liver and kidney toxicity, taking 20g of Ganoderma lucidum, 15g of Codonopsis pilosula, 15g of Poria cocos, 30g of Scutellaria barbata, 30g of Hedyotis diffusa, 30g of raw Coix seeds, 5g of frankincense, 5g of Myrrh, 10g of stir-fried Atractylodes macrocephala, 10g of Citrus aurantium, 10g of Bupleurum chinense, 6g of Pinellia ternata, and 6g of Licorice, mixing, adding 10 times the weight of water to soak for 2h, boiling and then decocting for 2h, filtering while hot to obtain a filtrate; adding 10 times the weight of water to the remaining drug residue, and operating in the same way. After that, the filtrate is combined and concentrated on a rotary evaporator, and concentrated to 132.5ml by a rotary evaporator to prepare a Chinese medicine water extract with a drug material concentration of 1.45g / mL.
[0013] experiment: 1. Cell lines Mouse pancreatic cancer PANC02 cell line was purchased from Procell, catalog number CL-0736.
[0014] 2. Experimental Animals Twenty C57BL / 6 male mice, 6 weeks old, weighing 20-21.5 g, were provided by Liaoning Changsheng Biotechnology Co., Ltd. Animal production certificate number: SYXK (Liao) 2024-0002. The experimental animals were raised and managed in accordance with SPF animal management requirements.
[0015] 3. Modeling A mouse subcutaneous transplant tumor model of mouse pancreatic cancer PANC02 cells was established. The mouse pancreatic cancer cell line PANC02 was subcultured in vitro and digested with trypsin to prepare a cell suspension. 1.5×10 6 0.1 mL of cell suspension was inoculated subcutaneously in the right hind limb of mice, and the tumor formation was observed and recorded every day.
[0016] 4. Grouping and intervention After one week of adaptive feeding, 20 C57BL / 6 mice were randomly divided into a control group, a compound group (the Chinese medicine preparation of the present invention), a gemcitabine group (100 mg / mL), and a combination group (the Chinese medicine preparation of the present invention + gemcitabine) according to the random number table method, with a total of 4 groups, 5 mice in each group. 14 days after modeling, the tumor volume was about 100mm 3 The intervention started at 1:00 pm. The control group was gavaged with normal saline (0.2 mL / 10 g per mouse, the same volume for the following gavages), once a day; the gemcitabine group was intraperitoneally injected (0.1 mL / 10 g per mouse, the same volume for the following gavages), once every 3 days; the Chinese medicine group and the combination group were gavaged with Chinese medicine preparations, once a day, and the combination group was simultaneously given gemcitabine intraperitoneally, once every 3 days. The intervention lasted for 14 days, and the weight and tumor volume of the tumor-bearing mice were measured and recorded every day.
[0017] 5. Detection methods for treating pancreatic cancer in each experimental group of the present invention After the start of drug administration, the body weight of mice was measured every day, and a curve of the change of mouse body weight over time was drawn to evaluate the change of mouse body weight after drug administration.
[0018] After the start of drug administration, the length and width of the tumor were measured every day, and the tumor volume was calculated according to the formula (length * width). 2 ) / 2 Calculate the tumor volume and plot the curve of tumor volume changing with time.
[0019] After the experiment, all tumor-bearing mice were killed, tumor tissues were isolated, weighed, photographed, and tumor mass statistics were drawn. The isolated tumor tissues were then washed with saline, fixed with paraformaldehyde, and sent to Wuhan Saiweier Biotechnology Co., Ltd. for sectioning, and HE staining was performed after the sections were retrieved.
[0020] 6. Method for detecting the effect of Chinese medicine preparations on gemcitabine-induced hepatotoxicity The liver and kidney function of the serum of each experimental group was tested using Mindray BS-240 Vet instrument. The specific test steps and methods were carried out according to the instructions of the kit.
[0021] The separated liver and kidney tissues were washed with physiological saline, fixed with paraformaldehyde, and sent to Wuhan Saiweier Biotechnology Co., Ltd. for sectioning. After the sections were retrieved, HE staining was performed.
[0022] 7. Statistical methods All data were calculated using SPSS 16.0 software. The measurement data were expressed as mean ± standard deviation (Mean ± SD). The independent sample t test was used for comparison between groups. P ≤ 0.05 was considered statistically significant.
[0023] 8. Experimental Results 8.1 Results of pancreatic cancer treatment in each experimental group The weight changes of mice in each experimental group after 1-14 days of pancreatic cancer treatment are as follows Figure 1 The results showed that compared with the control group, the weight loss in the gemcitabine group was the most obvious, and the combination of the Chinese medicine preparation of the present invention and gemcitabine could alleviate the weight loss of mice caused by gemcitabine. The changes in tumor volume of each experimental group after 1-14 days of pancreatic cancer treatment are as follows Figure 2 shown.
[0024] The tumor mass of each experimental group after treatment of pancreatic cancer was as follows Figure 3 As shown, Figure 3 **p≤0.01, ***p≤0.001, ****p≤0.0001 compared with the control group.
[0025] The tumor size of each experimental group after treatment of pancreatic cancer was as follows Figure 4 Shown HE staining of tumor tissue sections after treatment of pancreatic cancer in each experimental group is shown below. Figure 5 As shown. Figure 5 It can be seen that the nuclear-cytoplasmic ratio of tumor cells in the control group was high, the nested cells were arranged neatly and tightly, the boundaries were clear, and there was no obvious sign of cell necrosis. However, in the compound group, gemcitabine group and combination group, the tumor cell nuclei gradually shrank and became smaller, and the arrangement was loose; diffuse large-scale necrosis of tumor cells was found in the gemcitabine group and combination group.
[0026] The results showed that compared with the control group, the tumor volume and tumor mass of the other experimental groups were reduced, and the reduction in the combination group was the most obvious. The tumor inhibition rates of the compound group, gemcitabine group and combination group were 44.90%, 81.92% and 94.36% respectively. The Chinese medicine preparation of the present invention has a certain inhibitory effect on tumor growth, but the inhibitory effect on tumors is stronger when combined with gemcitabine. Although the tumor inhibition rate of the compound + gemcitabine group is higher than that of the gemcitabine group, the difference is not statistically significant.
[0027] 4.2 The test results of each experimental group in improving gemcitabine-induced hepato-renal toxicity are shown in Table 1.
[0028] Table 1 Comparison of serum liver and kidney function indicators in each group of mice
[0029] In Table 1, *p≤0.05, **p≤0.01, compared with the control group; # p≤0.05, ## p≤0.01, ### p≤0.001, compared with the gemcitabine group.
[0030] HE staining of liver and kidney tissues in each experimental group after treatment of pancreatic cancer Figure 6 As shown. Figure 6 It can be seen that compared with the control group, there was no significant difference in the hepatic and renal function indicators in the HE staining and serum of the compound group. In the HE staining of the gemcitabine group, the kidney damage, the glomerular capsule cavity became obvious, partly adhered to the glomerulus, the glomerular capillaries dilated and filled with blood cells, the renal tubular cavity became larger, and blood cells infiltrated; liver damage, with the central vein of the liver as the center, was photographed, and the gemcitabine group showed obvious inflammatory cell aggregation, inflammatory infiltration, and hepatocyte necrosis; at the same time, serum liver and kidney function indicators were compared, and the gemcitabine group was significantly increased compared with the control group. After the Chinese medicine preparation of the combination group of the embodiment of the present invention and gemcitabine were co-administered, the enlargement of the glomerular capsule cavity and the renal tubular cavity was alleviated, hepatocyte necrosis was significantly alleviated, inflammatory infiltration was alleviated, and serum indicators were reduced, with statistical differences.
[0031] The experimental results show that the Chinese medicine preparation of the embodiment of the present invention can be used in combination with gemcitabine to treat pancreatic cancer and improve the liver and kidney toxicity caused by gemcitabine in the treatment of pancreatic cancer. There is no need to reduce the treatment dose or interrupt the treatment during treatment, thereby achieving the purpose of effectively treating pancreatic cancer.
Claims
1. A Chinese medicine preparation that can be used in combination with gemcitabine to treat pancreatic cancer and improve liver and kidney toxicity, which is a Chinese medicine aqueous extract, Features The traditional Chinese medicine consists of the following components in parts by mass: 10-40 ganoderma lucidum, 7.5-30 codonopsis pilosula, 7.5-30 poria cocos, 15-60 barbata scabra, 15-60 oldenlandia diffusa, 15-60 raw coix seeds, 2.5-10 frankincense, 2.5-10 myrrh, 5-20 stir-fried atractylodes macrocephala, 5-20 immature bitter orange, 5-20 bupleurum, 3-12 pinellia ternata, and 3-12 liquorice.
Citation Information
Patent Citations
Composition of traditional Chinese medicine extracts for treating pancreatic cancer
CN108434223A
Application of fisetin in combined gemcitabine pancreatic cancer treatment
CN113679710A
